Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2-1-2019

An observational study of end-tidal carbon dioxide trends in
general anesthesia
Annemarie Akkermans
University Medical Center Utrecht

Judith A R van Waes
University Medical Center Utrecht

Aleda Thompson
University of Michigan - Ann Arbor

Amy Shanks
University of Michigan - Ann Arbor

Linda M Peelen
University Medical Center Utrecht

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Akkermans, Annemarie; van Waes, Judith A R; Thompson, Aleda; Shanks, Amy; Peelen, Linda M; Aziz,
Michael F; Biggs, Daniel A; Paganelli, William C; Wanderer, Jonathan P; Helsten, Daniel L; Kheterpal,
Sachin; van Klei, Wilton A; and Saager, Leif, ,"An observational study of end-tidal carbon dioxide trends in
general anesthesia." Canadian journal of anaesthesia. 66,2. . (2019).
https://digitalcommons.wustl.edu/open_access_pubs/9584

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Annemarie Akkermans, Judith A R van Waes, Aleda Thompson, Amy Shanks, Linda M Peelen, Michael F
Aziz, Daniel A Biggs, William C Paganelli, Jonathan P Wanderer, Daniel L Helsten, Sachin Kheterpal, Wilton
A van Klei, and Leif Saager

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/9584

Can J Anesth/J Can Anesth (2019) 66:149–160
https://doi.org/10.1007/s12630-018-1249-1

REPORTS OF ORIGINAL INVESTIGATIONS

An observational study of end-tidal carbon dioxide trends
in general anesthesia
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Abstract
Purpose Despite growing evidence supporting the
potential benefits of higher end-tidal carbon dioxide
(ETCO2) levels in surgical patients, there is still
insufficient data to formulate guidelines for ideal
intraoperative ETCO2 targets. As it is unclear which
intraoperative ETCO2 levels are currently used and
whether these levels have changed over time, we

Presentation: Preliminary data for this study were presented as a
poster at the American Society of Anesthesiologists Annual Meeting
on October 22, 2017 in Boston.

investigated the practice pattern using the Multicenter
Perioperative Outcomes Group database.
Methods This retrospective, observational, multicentre
study included 317,445 adult patients who received
general anesthesia for non-cardiothoracic procedures
between January 2008 and September 2016. The primary
outcome was a time-weighted average area-under-thecurve (TWA-AUC) for four ETCO2 thresholds (\ 28, \ 35,
\ 45, and [ 45 mmHg). Additionally, a median ETCO2
was studied. A Kruskal-Wallis test was used to analyse
differences between years. Random-effect multivariable
logistic regression models were constructed to study
variability.
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Results Both TWA-AUC and median ETCO2 showed a
minimal increase in ETCO2 over time, with a median
[interquartile range] ETCO2 of 33 [31.0–35.0] mmHg in
2008 and 35 [33.0–38.0] mmHg in 2016 (P \0.001). A
large inter-hospital and inter-provider variability in
ETCO2 were observed after adjustment for patient
characteristics,
ventilation
parameters,
and
intraoperative blood pressure (intraclass correlation
coefficient 0.36; 95% confidence interval, 0.18 to 0.58).
Conclusions Between 2008 and 2016, intraoperative
ETCO2 values did not change in a clinically important
manner. Interestingly, we found a large inter-hospital and
inter-provider variability in ETCO2 throughout the study
period, possibly indicating a broad range of tolerance for
ETCO2, or a lack of evidence to support a specific targeted
range. Clinical outcomes were not assessed in this study
and they should be the focus of future research.
Résumé
Objectif Malgré une accumulation de données probantes
suggérant des avantages de taux plus élevés de dioxyde de
carbone en fin d’expiration (ETCO2) chez les patients
chirurgicaux, nous ne disposons pas encore d’assez de
données pour formuler des lignes directrices sur les cibles
peropératoires idéales de l’ETCO2. Comme nous ne savons
effectivement pas avec certitude quels taux peropératoires
d’ETCO2 sont actuellement utilisés et si ces taux ont
changé au fil du temps, nous avons étudié l’évolution de la
pratique en utilisant la base de données du MPOG
(Multicenter Perioperative Outcomes Group).
Méthodes Cette étude multicentrique rétrospective
observationnelle a inclus 317 445 patients adultes ayant
reçu une anesthésie générale pour des procédures non
cardiothoraciques entre janvier 2008 et septembre 2016.
Le critère d’évaluation principal était une aire sous la
courbe moyenne pondérée en fonction du temps (ASC-mT)
pour quatre seuils d’ETCO2 (\ 28, \ 35, \ 45 et
[ 45 mmHg). De plus, une ETCO2 médiane a été
étudiée. Un test de Kruskal-Wallis a permis d’analyser
les différences entre les années. Des modèles de régression
logistique multifactorielle à effet aléatoire ont été
construits pour étudier la variabilité.
Résultats L’ASC-mT et l’ETCO2 médiane ont montré une
augmentation minime de l’ETCO2 au fil du temps, avec une
valeur médiane [plage interquartile] de l’ETCO2 de 33
[31,0 à 35,0] mmHg en 2008 et 35 [33,0 à 38,0] mmHg en
2016 (P \ 0,001). Une grande variabilité entre les
hôpitaux et prestataires de l’ETCO2 a été observée après
ajustement pour les caractéristiques des patients, les
paramètres de ventilation et la pression artérielle
peropératoire (coefficient de corrélation intracatégorie :
0,36; intervalle de confiance à 95 % : 0,18 à 0,58).
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Conclusions Entre 2008 et 2016, les valeurs
peropératoires de l’ETCO2 n’ont pas varié d’une
manière importante sur le plan clinique. Il est intéressant
de noter que nous avons trouvé une grande variabilité de
l’ETCO2 entre hôpitaux et prestataires tout au long de la
période d’étude témoignant peut-être d’une vaste plage de
tolérance de l’ETCO2 ou d’un manque de données
probantes pour soutenir une valeur cible spécifique.
L’évolution clinique n’a pas été analysée au cours de
cette étude et elle devra être le centre d’intérêt de futures
recherches.

Historically, it has been common practice to maintain
hypocapnia (arterial carbon dioxide pressure (PaCO2)\ 35
mmHg) during general anesthesia.1,2 Intraoperative endtidal carbon dioxide (ETCO2) values around 30 mmHg
were frequently targeted, as hypercapnia (PaCO2 [ 45
mmHg) was considered to contribute to intraoperative
tachycardia and hypertension, thereby increasing the
oxygen demand of the myocardium.1,3 In contrast,
hypocapnia reduced the need for muscle relaxants and
additional anesthetics to prevent spontaneous ventilation.
Nevertheless, there is no good evidence to support the
benefit of hypocapnia, and some studies suggest benefits
for higher ETCO2 levels.1,4,5 First, it is easier to implement
low tidal volume ventilation.6,7 Second, hypercapnia
increases the cardiac output, resulting in an increase in
tissue oxygenation, which in turn may prevent surgical site
infections.1,8-10 Third, studies using different lung injury
models have shown that hypercapnia has protective,
immune-modulating properties that decrease the
inflammatory response.11-13 Fourth, hypercapnia may
increase lung parenchymal compliance13-15 and can
improve ventilation-perfusion matching in the lungs.1,12,16
Finally, normocapnia positively influences the neurologic
outcome because of vasoactive properties of PaCO2, which
is especially pronounced in already injured brains.17
Unfortunately, many studies focus on the critical care
population,
leaving
surgical
patients
underrepresented.1,2,4,5,8-10 Therefore, there is no strong
evidence of a benefit for higher CO2 tensions compared
with hypocapnia in perioperative patients.
To generate evidence to formulate guidelines on ETCO2
management during general anesthesia, we first need to
understand current clinical practice. To our knowledge, it is
unclear which target ETCO2 levels are currently used and
whether these levels have changed over time. Therefore,
this study aimed to investigate the practice pattern of
ETCO2 levels over time in non-cardiothoracic surgery. We
did not aim to study clinical outcomes. We hypothesized
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that the target ETCO2 level may have increased over time
in response to the existing evidence described above. To
further explore the practice pattern, we aimed to investigate
four subgroups separately: patients with chronic
obstructive pulmonary disease (COPD; subgroup 1);
patients undergoing intracranial or carotid artery surgery
(subgroup 2); and patients receiving laparoscopic surgery
with (subgroup 3) or without (subgroup 4) robot assistance.

Methods
For this multicentre, retrospective, observational study, we
used data from the Multicentre Perioperative Outcomes
Group (MPOG) database. The MPOG registry, data entry
process, and validation of data have been described in
detail previously.18,19 In brief, MPOG is a consortium of 47
hospitals in North America and Europe, collecting
perioperative data to facilitate outcomes research.
Institutional Review Board (IRB) approval for MPOG
was obtained from the University of Michigan Health
System, MPOG’s coordinating institution. Each
participating institution has separate IRB approval to
submit a limited set of perioperative data into the
centralized database for future use, without any direct
patient identifiers. Ethical approval for the current study
was provided by the University Medical Center Utrecht,
the leading institution for this project (May 2016, Number
16-282/C). The requirement for written informed consent
was waived. No additional IRB approval was sought from
other institutions. Additionally, the study protocol was
reviewed a priori and approved by the MPOG
Perioperative Clinical Research Committee (PCRC-0032,
September 2016).
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Fig. 1. These criteria were based on procedure type, a poor
clinical condition prior to anesthesia, and suspected
intraoperative hemodynamic instability to limit the risk
of artifacts and invalid ETCO2 values. Vasopressor use per
hour was used as a proxy for hemodynamic instability.
Additionally, we excluded patients who received one-lung
ventilation and ventilation by means of a laryngeal mask
airway. To ensure sufficient time for data collection, cases
with \ 40 min between incision and the end of the surgical
procedure were excluded. Furthermore, patients with \ 20
valid machine-generated ETCO2 measurements were
excluded.
A priori, we defined four subgroups of patients in whom
the target ETCO2 level was considered to possibly differ
from other patients: 1) patients with COPD, as their awake
PaCO2 level may be increased and therefore a higher
ETCO2 may be accepted20; 2) patients undergoing
intracranial and carotid artery surgery, as these
interventions may compromise cerebral perfusion and
therefore warrant a strict control of ETCO2;1,17 and
patients receiving laparoscopic surgery with or without
robot assistance (subgroups 3 and 4 respectively), as
insufflation with carbon dioxide can increase the PaCO2,
therefore higher ETCO2 levels may need to be
tolerated.21-23 We differentiated between laparoscopic
surgery with and without robot assistance, since
Trendelenburg positioning can further increase the
PaCO2.22 All four subgroups were excluded from the
primary analysis to avoid confounding the observed change
in ETCO2 levels over time, especially because of an
increasing utilization of laparoscopic over open
procedures. Patients eligible for multiple groups were
excluded from all analyses.
Outcome

Patients
This study included all adult patients C 18 yr who received
general anesthesia between I January, 2008 and 9 January,
2016 at eight academic institutions affiliated with MPOG:
University of Michigan Health System, Ann Arbor,
Michigan; Oregon Health & Science University, Portland,
Oregon; University of Oklahoma Health Sciences Center,
Oklahoma City, OK; Washington University School of
Medicine, St. Louis, MO; University of Vermont Medical
Center, Burlington, VT; Vanderbilt University, Nashville,
TN; University Medical Center Utrecht, Utrecht, the
Netherlands; and University of Pennsylvania Health
System, Philadelphia, PA, USA. Only institutions
submitting data for all variables mentioned below were
selected for this study. For patients who received general
anesthesia more than once within 30 days, only the first
case was included. Exclusion criteria are presented in

The primary outcome was ETCO2 stratified into four
groups (\ 28, \ 35, \ 45, and [ 45 mmHg) and the areaunder-the-curve for each specific threshold was estimated
with adjustment for the total measurement time, resulting
in a time-weighted average area-under-the-curve (TWAAUC) per threshold. Patients could be binned into multiple
groups. Patients with at least one valid ETCO2 \28 mmHg
were binned into the \ 28 mmHg group, but these data
were also used for the \ 35 mmHg and \ 45 mmHg
groups, respectively. If patients also had at least one valid
ETCO2 value [ 45 mmHg, the corresponding TWA-AUC
was binned into the [ 45 mmHg group.
To aid interpretation and clinical applicability, a median
ETCO2 per case was obtained as a secondary outcome
measure. A priori, a relative change of 10% in median
ETCO2 over the entire study period was considered to be
clinically relevant.
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Data collection
Data collection for intraoperative variables started ten
minutes after surgical incision to ignore hyper- and
hypocapnia that may follow mask ventilation and
intubation during induction of anesthesia, and to allow
the ETCO2 to reach a set level. Data collection ended ten
minutes prior to the end of the surgical dressing to ignore
increased values of ETCO2 that may be accepted to
establish spontaneous ventilation. When the exact incision
time was not registered, data collection started 20 min after
anesthesia induction. Only valid ETCO2 values were used
(see Table 1S, available as Electronic Supplementary
Material for the artifact filter). Data were collected for
ventilation parameters (tidal volume, respiratory rate,
positive-end-expiratory pressure (PEEP), respiratory
minute volume (RMV)) and mean arterial blood pressure
(MAP) as potential confounders. Mean arterial pressure
and ventilation parameters, including ETCO2, were
measured continuously during general anesthesia by
automated interfaces. An average of these results was
recorded every minute in the anesthesia record-keeping
system and stored in the centralized MPOG database.
Preoperative data on sex, height, body mass index
(BMI), age, and American Society of Anesthesiologists
(ASA) physical status were collected as covariates.24 For
every case, we recorded the institution and determined the
primary anesthesia provider, defined as the supervising
anesthesiology faculty and primary anesthesia caregiver
(either nurse anesthetist or resident) that provided
anesthesia for at least 75% of the time.
Statistical analysis
Descriptive statistics were computed using frequencies and
percentages for categorical variables and medians with
interquartile ranges [IQR] for continuous data after
checking continuous variables for normality using the
Kolmogorov-Smirnov test.
Differences in baseline characteristics, ventilation
parameters, and mean MAP between the primary cohort
and the subgroups and between the beginning and end of
the study were analyzed using a Kruskal-Wallis test.
For all four thresholds, the TWA-AUC of each patient
was computed from minute-level ETCO2 values using a
fitted cubic spline curve (see Figure available as
Electronic Supplementary Material showing the method
to calculate the area-under-the-curve). For every case, a
median was calculated for tidal volume, respiratory rate,
PEEP, and RMV. We determined the mean MAP for
every case, as a summary measure for the overall blood
pressure.

123

A. Akkermans et al.
Fig. 1 Flow chart. ASA = American Society of Anesthesiologist; c
CPT = current procedural terminology; ETCO2 = end-tidal carbon
dioxide. LMA = laryngeal mask airway; MPOG = Multicenter
Perioperative Outcomes Group. *Blood transfusion [ two units was
defined as: more than two units of packed cells or whole blood or
more than 600 mL of cell saver blood during general anesthesia.
Patients were excluded when they met the inclusion criteria of more
than one subgroup: e.g., chronic obstructive pulmonary disease
(COPD) and laparoscopic surgery. àOnly the first case within 30 days
was included

Both the TWA-AUC and median ETCO2 were plotted
over time and values were compared between years using a
Kruskal-Wallis test. Medians and IQR were reported.
Prior to the start of this study, we surveyed all
participating centres to gain insight into target ETCO2
levels and factors that might have influenced these levels
during the study period. The full survey can be found in the
Supplemental Material. When abrupt changes in ETCO2
were reported by at least half of all institutions, an
interrupted time series (ITS) analysis was considered.
To examine variation in ETCO2, patient characteristics
were compared between patients with a median ETCO2 \
5th percentile, between the 5th and 95th percentile, and [
95th percentile using a Kruskal-Wallis test. To examine
variation between and within each institution, six mixedeffect multivariable logistic regression models were built.
A positive TWA-AUC ETCO2 [ 45 mmHg (meaning that
at least one ETCO2 value per case was [ 45 mmHg) was
used as a binary outcome measure in all models. Before
any regression models were constructed, all variables under
consideration for model inclusion were checked for
collinearity using the condition index. If the condition
index was [ 30, a Pearson’s correlation matrix was
developed. Those variables deemed to be collinear (defined
as a correlation of C 0.70) were either combined into a
single variable or removed. All non-collinear variables
were entered into the models. The included fixed effects
were selected based upon clinical relevance: age (binned
per decade, reference group 18–30), sex, BMI (binned into
\18.5, 18.5–24.9 (reference group), 25.0–29.9, 30.0–34.9,
35.0–39.9, C 40.0 kgm-2), ASA class (I or II vs III, IV,
V), median tidal volume (binned by ideal body weight into
\ 6, 6–8 (reference group), 8–10, [ 10 mLkg-1), median
respiratory rate (binned into\12, 12–16 (reference group),
16–20, [ 20 min-1), median PEEP (binary, \ 5 or C 5
cmH2O), mean MAP (\ 65, 65–80 (reference group), [ 80
mmHg), and year of the procedure. All six mixed-effects
models contained the same fixed effects with differing
random effects between the models. The first model used
institution as a random effect to examine the variation
between institutions; the second model used primary
anesthesia caregiver, and the third used supervising
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anesthesiology faculty as random effects to examine how
much of the variation could be explained by inter-provider
variability. The fourth model used supervising
anesthesiology faculty nested within institution as a
random effect and the fifth model used primary
anesthesia caregiver nested within institution to further
explore variation due to preferences of a provider within a
specific institution. The final model was built with primary
anesthesia
caregiver
nested
within
supervising
anesthesiology faculty, which was again nested within
institution, as the random effect. This model was built to
explore how much of the variation could be explained by a
particular anesthesia care team in a specific institution.
Measures of effect size for random effects were reported as
intraclass correlation coefficients (ICC) and median odds
ratios (MOR) with corresponding 95% confidence intervals
(CI).25
All analyses were conducted for the general cohort and
the subgroups separately. A P value of 0.05 was considered
statistically significant for all analyses.
The analyses were conducted using SAS v. 9.4 (SAS
Institute, Cary, NC, USA) and Stata v. 13.1 (StataCorp

LLC; College Station, TX, USA). The study was conducted
in adherence to the STROBE statement for observational
research.26

Results
One million, seven hundred and ninety-four thousand,
seven hundred and seventy-three patients met the initial
inclusion criteria of general anesthesia and age. After
application of all a priori defined exclusion criteria and
after exclusion of invalid observations, 317,445 patients
were eligible. We included 245,725 patients in our primary
analysis and 71,720 patients in different subgroups
(Fig. 1). Patient characteristics for the primary cohort and
the subgroups are described in Table 1. Additionally,
differences in patient characteristics between 2008 and
2016 are shown in Table 2. Over time, patients were
slightly older, had a higher BMI, and had a higher ASA
class. RMV slightly decreased over time, whereas the mean
MAP increased over time. The duration of both the
procedure and general anesthesia decreased over time.

Table 1 Baseline characteristics for the general cohort and the subgroups
General cohort Intracranial and carotid artery
(n = 245,725) surgery
(n = 12,527)

Laparoscopic
surgery
(n = 44,507)

Robotic laparoscopic
surgery
(n = 12,977)

COPD
(n = 1709)

Age (yr)*

51 [38–63]

53 [39–64]

49 [36–60]

60 [52–66]

65 [55–73]

Sex (female)

124782 (50.8)

6442 (51.4)

28661 (64.4)

3364 (25.9)

810 (47.40)

ASA physical status

27738 (11.3)

735 (5.9)

4494 (10.1)

513 (4.0)

0 (0.0)

I

125488 (51.1)

4736 (37.8)

23039 (51.8)

7705 (59.4)

341 (20.0)

II

84835 (34.5)

6447 (51.5)

16351 (36.7)

4667 (36.0)

1173 (68.6)

III

7603 (3.1)

598 (4.8)

622 (1.4)

92 (0.7)

192 (11.2)

IV

61 (0.02)

11 (0.1)

1 (0.0)

0 (0.0)

3 (0.2)

Height (cm)*
BMI (kgm-2)*

170 [163–178]

170 [163–178]

168 [162–175] 175 [168–182]

170 [160–178]

27.8 [24.1–
32.7]

27.3 [23.8–31.7]

29.8 [25.1–
37.3]

28.7 [25.6–32.6]

27.2 [23.4–
32.6]

Median RMV (mLmin-1)*

5571 [4660–
6590]

6012 [4960–7238]

6288[5391–
7330]

6720 [5860–7692]

5560 [4728–
6504]

V

Median respiratory rate*

10 [9–12]

12 [10–13]

12 [10–14]

12 [10–14]

10 [9–12]

Median ETCO2 (mmHg)*

34.0 [32.0–
36.0]

32.0 [29.0–34.0]

36.0 [34.0–
38.0]

36.0 [33.0–38.0]

34.0 [32.0–
37.0]

83 [77–89]

Mean MAP (mmHg)*

78 [72–85]

81 [75–87]

82 [76–89]

Duration of general anesthesia
(min)*

170 [129–232]

233 [173–325]

167 [126–225] 251 [213–301]

197 [150–265]

Duration of surgery (min)*

103 [70–155]

133 [84–211]

106 [72–153]

122 [83–186]

179 [145–226]

80 [74–86]

*Median [interquartile range]; Count and %
ASA = American Society of Anesthesiologist; BMI = body mass index; COPD = chronic obstructive pulmonary disease; ETCO2 = end-tidal
carbon dioxide; MAP = mean arterial pressure; RMV = respiratory minute ventilation
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Table 2 Baseline characteristics and ETCO2 levels for 2008 and 2016
Case year 2008
(n = 23434)

Case year 2016
(n = 18797)

P Value

Age (yr)

50 [38–62]

52 [37–64]

\ 0.001*

Sex (female)à

11922 (50.9)

9511 (50.6)

General cohort
\ 0.001*
\ 0.001*

ASA physical statusà
I

3148 (13.4)

1965 (10.5)

II

12477 (53.2)

9209 (49.0)

III

7130 (30.4)

6986 (37.2)

IV

672 (2.9)

632 (3.4)

V

7 (0.03)

5 (0.03)

Height (cm)
BMI (kgm-2)

170 [163–178]
27.4 [23.9–32.1]

170 [163–178]
28.09 [24.2–33.1]

0.14
\ 0.001

Median RMV (mLmin-1)

5665 [4744–6708]

5480 [4572–6468]

\ 0.001

Mean MAP

77 [71–84]

80 [73–86]

\ 0.001

Duration of general anesthesia (min)

178 [134–241]

167 [127–224]

\ 0.001

Duration of surgery (min)

106 [72–160]

102 [69–153]

\ 0.001*

TWA-AUC ETCO2 \ 28 mmHg

0.0 [0.0–1.0]

0.0 [0.0–0.0]

\ 0.001*

TWA-AUC ETCO2 \ 35 mmHg

169.0 [57.8–351.8]

45.4 [2.0–161.9]

\ 0.001*

TWA-AUC ETCO2 \ 45 mmHg

986.9 [573.5–1621.8]

713.2 [385.0–1218.1]

\ 0.001*

TWA-AUC ETCO2 [ 45 mmHg

0.0 [0.0–0.0]

0.0 [0.0–2.73]

\ 0.001*

Median ETCO2 (mmHg)

33.0 [31.0–35.0]

35.0 [33.0–38.0]

\ 0.001*

Intracranial and carotid artery surgery
TWA-AUC ETCO2 \ 28 mmHg

0.0 [0.0–35.0]

0.0 [0.0–17.0]

0.03*

TWA-AUC ETCO2 \ 35 mmHg

376.5 [145.0–812.5]

181.0 [28.4–658.3]

\ 0.001*

TWA-AUC ETCO2 \ 45 mmHg

1581.3 [841.5–2680.7]

1238.9 [622.1–2292.3]

\ 0.001*

TWA-AUC ETCO2 [ 45 mmHg

0.0 [0.0–0.0]

0.0 [0.0–0.0]

0.001*

Median ETCO2 (mmHg)
Laparoscopic surgery

31.6 [29.0–33.0]

33.0 [30.0–36.0]

\ 0.001*

TWA-AUC ETCO2 \ 28 mmHg

0.0 [0.0–0.0]

0.0 [0.0–0.0]

\ 0.001*

TWA-AUC ETCO2 \ 35 mmHg

76.3 [19.0–193.3]

17.3 [0.34–77.1]

\ 0.001*

TWA-AUC ETCO2 \ 45 mmHg

856.9 [489.7–1408.2]

574.0 [327.5–990.2]

\ 0.001*

TWA-AUC ETCO2 [ 45 mmHg

0.0 [0.0 to1.0]

0.0 [0.0–3.58]

\ 0.001*

Median ETCO2 (mmHg)

35.0 [33.0–37.0]

37.0 [35.0–40.0]

\ 0.001*

TWA-AUC ETCO2 \ 28 mmHg

0.0 [0.0–0.0]

0.0 [0.0–0.0]

0.03*

Robotic laparoscopic surgery
TWA-AUC ETCO2 \ 35 mmHg

140.2 [31.9–327.9]

58.5 [7.0–187.0]

\ 0.001*

TWA-AUC ETCO2 \ 45 mmHg

1538.9 [1099.0–2028.5]

1306.3 [849.1–1884.4]

\ 0.001*

TWA-AUC ETCO2 [ 45 mmHg

0.0 [0.0–4.0]

0.0 [0.0–19.0]

\ 0.001*

Median ETCO2 (mmHg)

35.0 [33.0–37.7]

37.0 [35.0–39.0]

\ 0.001*

TWA-AUC ETCO2 \ 28 mmHg

0.0 [0.0–2.0]

0.0 [0.0–0.0]

0.06

TWA-AUC ETCO2 \ 35 mmHg
TWA-AUC ETCO2 \ 45 mmHg

162.4 [41.3–394.0]
1151.0 [658.0–1989.1]

22.8 [1.5–164.5]
728.9 [390.4–1264.8]

\ 0.001*
\ 0.001*

COPD

TWA-AUC ETCO2 [ 45 mmHg

0.0 [0.0–0.24]

0.0 [0.0–21.6]

\ 0.001*

Median ETCO2 (mmHg)

34.0 [32.0–36.0]

36.0 [ 34.0–39.0]

\ 0.001*

*Statistically significant at a level of significance of P \ 0.05 Median [interquartile range]. àCount and %
ASA = American Society of Anesthesiologist; BMI = body mass index; COPD = chronic obstructive pulmonary disease. ETCO2 = end-tidal
carbon dioxide; MAP = mean arterial pressure; RMV = respiratory minute ventilation; TWA-AUC = time-weighted average area-under-thecurve
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Variation in ETCO2

Fig. 2 Trend in TWA-AUC ETCO2 for four different thresholds. The
trend over time in mean time-weighted average area-under-the-curve
(TWA-AUC) per quarter for an end-tidal carbon dioxide levels
(ETCO2) of\28 mmHg,\35 mmHg,\45 mmHg, and[45 mmHg.
The TWA-AUC decreased over time for an ETCO2 threshold of\28,
\ 35, and \45 mmHg, whereas the TWA-AUC ETCO2 [ 45 mmHg
increased over time

Change in ETCO2 over time
The mean TWA-AUC per quarter of a year was plotted for
all four ETCO2 thresholds (Fig. 2, data for the general
cohort) and showed that more time was spent closer to or
above the threshold of 45 mmHg. There was a statistically
significant decrease in TWA-AUC from 2008 to 2016 for
an ETCO2 \ 28 mmHg, \ 35 mmHg, and \ 45 mmHg,
whereas a TWA-AUC ETCO2 [ 45 mmHg significantly
increased over time (Table 2). The median [IQR] ETCO2
was plotted over time (Fig. 3a) and showed a minimal
increase from 33 [31.0–35.0] mmHg in 2008 to 35 [33.0–
38.0] mmHg (P \ 0.001) in 2016.
Similar trends were obtained for the subgroups over
time (Fig. 3 and Table 2). Nevertheless, the ETCO2 was
lower for patients presenting for intracranial and carotid
artery surgery and higher for patients in the (robotic)
laparoscopic cohort and for patients with COPD (see also
Table 2S, available as Electronic Supplementary Material,
showing the median ETCO2 and TWA-AUC per threshold
for the general cohort and all subgroups).
In the survey, two out of eight (25%) institutions
reported a decrease in RMV between 2008 and 2016, and
one institution (12.5%) reported an increase in RMV.
Three institutions (37.5%) reported an increase in target
ETCO2 level varying between 2 and 5 mmHg. Since a
minority of institutions reported a change in time, we
refrained from conducting ITS analysis. Results from the
survey are summarized in Table 3S in the Electronic
Supplementary Material.
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The median ETCO2 plots showed a large spread between
the 10th and 90th percentile (Fig. 3). Characteristics of
patients with a median ETCO2 \ 5th percentile (\ 29
mmHg), between the 5th and 95th percentile (29–41
mmHg), and > 95th percentile (41 mmHg) were
compared (see Table 4S available as Electronic
Supplementary
Material
showing
the
baseline
characteristics by percentile). Patients with a higher
median ETCO2 were, on average, younger, had a higher
BMI, a lower ASA class, and were more often male. The
median RMV was lower for patients with a higher median
ETCO2. The duration of both general anesthesia and
surgery was longest for patients with an intermediate
ETCO2 (between 29 and 41 mmHg).
After adjusting for patient characteristics, ventilation
parameters, and mean MAP, an ICC of 0.18 (95% CI, 0.07
to 0.37) was found for a model using institution as a
random effect, 0.17 (95% CI, 0.16 to 0.19) for a model with
primary anesthesia caregiver as a random effect, and 0.12
(95% CI, 0.11 to 0.14) for a model with supervising
anesthesiology faculty as a random effect (Table 3). An
ICC of 0.36 (95% CI, 0.18 to 0.58) was found for a model
with primary anesthesia caregiver nested within a specific
supervising anesthesiology faculty, nested within a specific
institution, as a random effect. This corresponded with a
MOR of 1.98 (95% CI, 1.90 to 2.07). In this, the MOR can
be interpreted as the median increase in the odds of having
at least one ETCO2 value per case > 45 mmHg, when an
individual moves from a one cluster to another. The
subgroup consisting of patients with COPD was too small
to conduct random-effect multivariable logistic regression
models.

Discussion
Between 2008 and 2016, median ETCO2 levels increased
minimally, but this change did not meet the a prioridefined clinically relevant threshold of 10%. A large
variation in target ETCO2 levels was observed between
institutions and between providers for the general cohort
and all subgroups. Interestingly, only a minority of this
variation could be attributed to the institution and
anesthesia provider, while controlling for patient
characteristics. The amount of variability that could be
attributed to institution and primary anesthesia caregiver
was overall slightly larger than the amount that could be
attributed to the supervising anesthesiology faculty, except
for intracranial and carotid artery surgery, where the
preference of the supervising anesthesiology faculty

End-tidal CO2 trends in general anesthesia

Fig. 3 Trend in median ETCO2 over time. The boxplots show an
increase in median end-tidal carbon dioxide (ETCO2) values between
2008 and 2016 for the general cohort (A) and the subgroups (B–E).
The triangle represents the mean, the whiskers represent the spread
between the 10th and 90th percentile. The median ETCO2 was lower
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for patients presenting for intracranial and carotid artery surgery (B)
compared with the general cohort. The median ETCO2 was higher for
patients in the (robotic) laparoscopic cohort (C, D) and for patients
with chronic obstructive pulmonary disease (COPD) (E) compared
with the general cohort (A)
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Table 3 Institutional and provider variation
Random effect per model*

General cohort
n = 245,725

Intracranial and
carotid artery
surgery
n = 12,527

Laparoscopic
surgery
n = 44,507

Robotic
laparoscopic
surgery
n = 12,977

Institution

ICC (95% CI)

0.18 (0.07–0.37)

0.14 (0.05–0.33)

0.11 (0.04–0.26)

0.22 (0.09–0.44)

Supervising anesthesiology faculty

MOR (95% CI)
ICC (95% CI)

1.96 (1.28–6.32)
0.12 (0.11–0.14)

1.66 (1.19–4.55)
0.18 (0.12–0.25)

1.44 (1.13–2.95)
0.05 (0.04–008)

2.36 (1.34–12.15)
0.19 (0.15–0.24)

MOR (95% CI)

1.56 (1.45–1.69)

1.96 (1.54–2.84)

1.20 (1.13–1.29)

2.10 (1.75–2.69)

ICC (95% CI)

0.17 (0.16–0.19)

0.15 (0.10–0.21)

0.14 (0.12–0.16)

0.30 (0.26–0.35)

MOR (95% CI)

1.91 (1.79–2.06)

1.79 (1.44–2.24)

1.68 (1.55–1.84)

3.86 (2.91–5.51)

Supervising anesthesiology faculty
nested within institution

ICC (95% CI)

0.23 (0.09–0.49)

0.22 (0.10–0.40)

0.12 (0.03–0.37)

0.18 (0.05–0.46)

MOR (95% CI)

1.08 (1.06–1.10)

1.42 (1.23–1.83)

1.12 (1.03–1.42)

1.05 (1.02–1.13)

Primary anesthesia caregiver nested
within institution

ICC (95% CI)

Did not converge

0.23 (0.11–4.23)

0.17 (0.08–.31)

0.31 (0.14–0.55)

1.34 (1.18–1.68)

1.26 (1.20–1.34)

1.39 (1.26–1.60)

Primary anesthesia caregiver nested
within supervising anesthesiology
faculty, nested within institution

ICC (95% CI)

0.36 (0.18–0.58)

0.26 (0.12–0.48)

0.27 (0.16–0.42)

0.37 (0.19–0.59)

MOR (95% CI)

1.98 (1.90–2.07)

1.21 (1.01–31.25)

1.29 (1.16–1.49)

2.06 (1.58–3.12)

Primary anesthesia caregiver

MOR (95% CI)

*Dependent variable: positive TWA-AUC ETCO2 [45 mmHg (yes/no). Fixed effects: age (binned per decade), body mass index (binned into\
18.5, 18.5–24.9, 25.0–29.9, 30.0–34.9, 35.0–39.9, C 40.0 kgm-2), sex, ASA class (I or II vs III, IV, or V), positive end-expiratory pressure
(binary,\5 or C 5mmHg), tidal volume (binned by ideal body weight into\6, 6–8, 8–10,[10 mLkg-1), median respiratory rate (binned into\
12, 12–16, 16–20, [ 20min-1), mean of the mean arterial blood pressure (binned \ 65, 65–80, [ 80 mmHg) and year of procedure. Random
effects differed per model and included institution, primary anesthesia caregiver, and/or attending anesthesiologist
The subgroup of patients with a history of chronic obstructive pulmonary disease was too small to conduct random-effect multivariable logistic
regression analyses
CI = confidence interval; ICC = intraclass correlation coefficient; MOR = median odds ratio

seemed to be more important than the effect of institution
and primary anesthesia caregiver.
Practice variation in targeted ETCO2 levels has not been
studied previously. Large practice variation across regions,
institutions, and physicians is reported throughout the
medical field.27 Previously, a variation of 18% in tidal
volume was shown to be attributable to institutional
variability.24 The same amount of variation could be
attributed to institutional variability in our study.
The large variation in ETCO2 found in this study may
have several implications. It raises the question whether
anesthesia providers care for any ETCO2 target at all, or at
least it could be theorized that ETCO2 levels are not as
important as maintaining, for example, adequate blood
pressure levels or oxygen saturation. Likely, there is
insufficient knowledge about the effects of ETCO2 levels to
guide anesthesia providers in targeting specific ETCO2
levels. We believe further exploration of the effect of
intraoperative ETCO2 levels on postoperative outcome is
required to determine what ETCO2 level should be aimed
for to improve patient outcome. This research group has
initiated two new projects to study the association between
intraoperative ETCO2 levels and postoperative pulmonary
complications, and the association between intraoperative
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ETCO2 levels and neurologic outcome in the neurosurgical
population.
As all retrospective analyses, this study has limitations.
First, we did not differentiate between spontaneous and
controlled ventilation, but we only included cases with
endotracheal tubes placed. By excluding cases managed
with laryngeal mask airways, the likelihood of spontaneous
breathing patterns was reduced significantly. It could be
argued that some of the residual spontaneous breathing
might lead to a higher ETCO2 level and that this may
explain the observed variation. Nevertheless, we would
expect that an inacceptable ETCO2 level (either hyper- or
hypocapnia) would be corrected by the anesthesia provider.
Therefore, since the aim of this study was to investigate
which levels are being accepted, we did not differentiate
between these ventilation methods. Second, the use of
certain ventilator modes might be associated with the
practice pattern in ETCO2 levels, e.g., a volume-controlled
ventilation mode with a specific default setting, but this
was not taken into account in this study. As became
apparent from the survey, the majority of institutions used
a strictly controlled default ventilation mode. Third, a
TWA-AUC is not easily applicable in daily practice.
Nevertheless, our primary aim was to investigate the

End-tidal CO2 trends in general anesthesia

practice pattern over time for further research purposes and
we believe that a median ETCO2 per case would not suffice
to summarize a case adequately. Four ranges of ETCO2 and
thus four different TWA-AUC values per case allowed us
better to summarize a very long case compared with one
overall value. The median ETCO2 was added as a
secondary outcome measure to aid interpretation and
clinical applicability. Fourth, the intraoperative timeframe used for data collection was chosen based upon
expert consensus. We aimed to collect data during a
relatively stable phase of general anesthesia. We checked
timeframes in randomly selected cases and found a good
correspondence with the maintenance phase of anesthesia.
Finally, although we adjusted the results for a large set of
potential confounders, residual confounding might be
present because of the retrospective nature of this study.

Conclusion
There was no clinically relevant change in intraoperative
ETCO2 levels between 2008 and 2016. Nevertheless, there
was a very large practice variation, even within institutions
and providers that could not be fully explained by
differences in patient or procedure characteristics.
Although existing literature suggests that ETCO2 levels
of 40 mmHg or higher might be associated with better
outcomes in mechanically-ventilated patients,4,5,9,17,28 this
is not reflected in current clinical anesthesia practice.
Clinical outcomes were not assessed in this study and
should be the focus of future research to formulate clear
guidelines.
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